RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Geneseeq, a Nanjing-Toronto genetic sequencing company, closed a C funding round of “hundreds of millions of RMB,” according to the company. Founded in 2008, Geneseeq focuses on genetic sequencing to provide personalized medicine for tumor related diseases. The company has a pan-genomic testing system that detects genetic abnormalities in 416 cancer-related genes. Each 100 million RMB would be worth $15 million, implying the funding totaled at least $30 million.
Source: China Biotoday